StemGenex(r) Continues to Announce Groundbreaking Stem Cell Therapies for MS Patients

Published: December 3, 2013 11:37 AM

New targeted stem cell therapy looks to improve MS patients dealing with incontinence complications.

La Jolla, California (PRWEB) December 03, 2013

StemGenex®, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases today announced the newest therapy to assist patients diagnosed with Multiple Sclerosis.

According to the National MS Society, at least 80% of people with MS experience bladder dysfunction. StemGenex believes a new therapy delivering adipose derived mesenchymal cells directly to the bladder may reduce the inflammation that is causing the patient’s incontinence.

Direct bladder targeting is the latest in a series of targeted therapies StemGenex® plans to announce in the next few months for patients dealing with degenerative diseases such as Parkinson’s, Alzheimer’s, COPD and of course Multiple Sclerosis. Earlier this month StemGenex announced a new intranasal stem cell therapy. The goal of this new technique is to encourage more stem cells to travel through the blood brain barrier to target the damage caused by MS.

Stem cell treatment studies are currently being offered by StemGenex to patients diagnosed with Multiple Sclerosis and other degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Parkinson’s and Alzheimer’s disease, stroke recovery and others. Rita Alexander, founder of StemGenex and the company’s first stem cell patient, insists that all patients be treated like they are one of our loved ones. “Hope, compassion, and the relentless pursuit for an end to these diseases are our primary focus.”

Continue

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews